Supplementary Table 2. Univariate linear regression analysis of percent change of htTKV and variables

	Univariate									
	Total (n = 108)		Total except for 1B (n = 107)		1C (n = 36)		1D (n = 37)		1E (n = 34)	
	ß	p-value	ß	p-value	ß	p-value	ß	p-value	ß	p-value
Age	0.053	0.18	0.056	0.19	0.101	0.23	0.05	0.42	0.145	0.12
Sex (male)	−0.689	0.32	−0.728	0.31	−1.424	0.27	−1.315	0.16	−0.243	0.91
Systolic blood pressure (mmHg)	−0.002	0.92	−0.003	0.92	0.029	0.53	−0.054	0.06	0.045	0.38
Diastolic blood pressure (mmHg)	0.006	0.84	0.006	0.85	0.023	0.70	−0.066	0.12	0.062	0.30
Baseline eGFR (mL/min/1.73 m^2)	−0.022	0.07	−0.022	0.07	−0.004	0.88	−0.008	0.64	−0.06	0.009
Baseline htTKV (mL/m)	0.001	0.04	0.001	0.046	0.003	0.21	0.001	0.53	0.002	0.06
Baseline urine osmolality (mOsm/kg)	−0.005	0.003	−0.005	0.003	−0.005	0.08	−0.007	0.046	−0.005	0.20
Change of urine osmolality (mOsm/kg)	0.004	0.02	0.004	0.03	0.005	0.11	0.006	0.02	0.001	0.83
Weight-adjusted dose of tolvaptan (mg/kg)	−0.278	0.86	−0.233	0.85	0.701	0.83	1.949	0.36	−3.327	0.33

eGFR, estimated glomerular filtration rate; CKD, chronic kidney disease; htTKV, height-adjusted total kidney volume.